The Role of the PAX8/PPARγ Fusion Oncogene in Thyroid Cancer
Author Information
Author(s): Kimberly A. Placzkowski, Honey V. Reddi, Stefan K. G. Grebe, Norman L. Eberhardt, Bryan McIver
Primary Institution: Mayo Clinic & Foundation
Hypothesis
PPARγ inhibition, downregulation, or insufficiency appears to be tumorigenic in the thyroid.
Conclusion
The PAX8/PPARγ fusion oncogene may play a significant role in the development of follicular thyroid carcinoma.
Supporting Evidence
- PPARγ is known for its role in cell cycle control and inflammation.
- PPARγ agonists have shown promising results in vitro for thyroid cancer treatment.
- Downregulation of PPARγ may be a key event in thyroid carcinogenesis.
Takeaway
Some thyroid cancers have a special gene change that can make them grow faster, and scientists are studying how to use this information to help treat patients better.
Methodology
The study involved reviewing genetic and molecular data related to thyroid cancer and the PAX8/PPARγ fusion gene.
Limitations
The findings are based on existing studies and may not be conclusive without larger, more comprehensive analyses.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website